Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MIST 
Milestone Pharmaceuticals Inc (MIST)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: MIST (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3.5
1 Year Target Price $3.5
| 0 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -68.76% | Avg. Invested days 22 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 169.14M USD | Price to earnings Ratio - | 1Y Target Price 3.5 |
Price to earnings Ratio - | 1Y Target Price 3.5 | ||
Volume (30-day avg) 4 | Beta 0.6 | 52 Weeks Range 0.62 - 2.75 | Updated Date 10/13/2025 |
52 Weeks Range 0.62 - 2.75 | Updated Date 10/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.84 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -50.33% | Return on Equity (TTM) -780.29% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 198264488 | Price to Sales(TTM) 77.32 |
Enterprise Value 198264488 | Price to Sales(TTM) 77.32 | ||
Enterprise Value to Revenue 81.44 | Enterprise Value to EBITDA -1.43 | Shares Outstanding 84994261 | Shares Floating 53456569 |
Shares Outstanding 84994261 | Shares Floating 53456569 | ||
Percent Insiders 3.37 | Percent Institutions 20.23 |
Upturn AI SWOT
Milestone Pharmaceuticals Inc
Company Overview
History and Background
Milestone Pharmaceuticals Inc., founded in 2003, is a biopharmaceutical company focused on developing and commercializing etripamil for cardiovascular indications. The company went public in 2019. The company has focused on bringing innovative therapies to market for cardiovascular diseases.
Core Business Areas
- Pharmaceutical Development: Milestone focuses on developing and commercializing innovative therapies for cardiovascular diseases.
Leadership and Structure
The leadership team comprises seasoned executives with experience in the pharmaceutical and biotechnology industries. The company structure follows a typical biopharmaceutical organization, with departments focused on research, development, clinical trials, and commercialization.
Top Products and Market Share
Key Offerings
- Etripril: Etripril is Milestone's investigational product, a calcium channel blocker nasal spray. It is being developed for the acute treatment of paroxysmal supraventricular tachycardia (PSVT). Milestone Pharmaceuticals' leading product is Etripamil. Competitors include Adenosine (Adenoscan, Adenocard), Verapamil and Diltiazem
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, long development timelines, and regulatory hurdles. The cardiovascular market is a significant segment within the pharmaceutical industry, driven by the prevalence of heart diseases.
Positioning
Milestone Pharmaceuticals is positioned as an innovative company focused on developing targeted therapies for cardiovascular conditions with Etripamil.
Total Addressable Market (TAM)
The market for PSVT treatments is estimated at $1.5 billion, positioning Milestone to capture significant market share if Etripamil is approved.
Upturn SWOT Analysis
Strengths
- Novel drug candidate (Etripril)
- Focused on a specific cardiovascular indication (PSVT)
- Experienced management team
Weaknesses
- Single product pipeline (Etripril)
- Reliance on clinical trial success
- Regulatory approval risks
Opportunities
- Expansion into other cardiovascular indications
- Potential for partnerships or collaborations
- Positive clinical trial results leading to market approval
Threats
- Competition from existing PSVT treatments
- Unfavorable clinical trial results
- Regulatory delays or rejection
Competitors and Market Share
Key Competitors
- BIIB
- PFE
- JNJ
Competitive Landscape
Milestone faced significant competition from established pharmaceutical companies with existing treatments for PSVT. Milestone's competitive advantage rested on the potential for etripamil to be a more convenient and effective treatment option.
Growth Trajectory and Initiatives
Historical Growth: The company experienced no revenue growth, only expenditures for R&D.
Future Projections: There is no prospect of future growth based on the most recent information.
Recent Initiatives: The company has halted research and is seeking strategic alternatives which could include a sale of the company.
Summary
Milestone Pharmaceuticals has struggled due to clinical trial failures and lack of revenues. As of the latest filings, the company has shifted focus and has no active operations or ongoing R&D programs with questionable viability. There is no growth to mention, the company is halting research and is seeking strategic alternatives which could include a sale of the company. Milestone does not look like a strong company.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Financial News Outlets
- Industry Reports
- Clinical Trial Data
Disclaimers:
The analysis provided is for informational purposes only and does not constitute investment advice. The information is based on available data and is subject to change. Investment decisions should be made based on individual risk tolerance and thorough due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Milestone Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Montreal, QC, Canada | ||
IPO Launch date 2019-05-09 | CEO, President & Director Mr. Joseph G. Oliveto M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 33 | Website https://www.milestonepharma.com |
Full time employees 33 | Website https://www.milestonepharma.com | ||
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.